iA Global Asset Management Inc. Boosts Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

iA Global Asset Management Inc. raised its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 30.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,122 shares of the biopharmaceutical company's stock after acquiring an additional 2,357 shares during the period. iA Global Asset Management Inc.'s holdings in Alnylam Pharmaceuticals were worth $2,460,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the business. GAMMA Investing LLC purchased a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth about $52,000. Truist Financial Corp bought a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter worth about $474,000. Gilbert & Cook Inc. increased its holdings in Alnylam Pharmaceuticals by 7.7% during the 4th quarter. Gilbert & Cook Inc. now owns 4,443 shares of the biopharmaceutical company's stock valued at $850,000 after purchasing an additional 317 shares during the period. First Trust Direct Indexing L.P. increased its stake in shares of Alnylam Pharmaceuticals by 13.3% during the fourth quarter. First Trust Direct Indexing L.P. now owns 2,898 shares of the biopharmaceutical company's stock valued at $555,000 after buying an additional 340 shares during the period. Finally, Los Angeles Capital Management LLC purchased a new stake in Alnylam Pharmaceuticals in the fourth quarter worth about $3,259,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Alnylam Pharmaceuticals

In other news, Director David E. I. Pyott sold 32,450 shares of the firm's stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $220.69, for a total value of $7,161,390.50. Following the transaction, the director now owns 136 shares of the company's stock, valued at $30,013.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director David E. I. Pyott sold 32,450 shares of the stock in a transaction on Monday, June 24th. The shares were sold at an average price of $220.69, for a total value of $7,161,390.50. Following the completion of the sale, the director now directly owns 136 shares of the company's stock, valued at $30,013.84. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CMO Pushkal Garg sold 2,103 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total transaction of $485,771.97. Following the transaction, the chief marketing officer now owns 15,609 shares in the company, valued at approximately $3,605,522.91. The disclosure for this sale can be found here. Insiders sold 103,148 shares of company stock worth $25,658,824 in the last three months. Corporate insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Stock Down 8.5 %

NASDAQ:ALNY traded down $24.32 on Friday, hitting $262.69. The stock had a trading volume of 3,762,558 shares, compared to its average volume of 864,553. The business's 50-day simple moving average is $255.96 and its two-hundred day simple moving average is $187.86. The stock has a market cap of $33.72 billion, a price-to-earnings ratio of -98.02 and a beta of 0.37. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $287.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.61. The business had revenue of $659.83 million for the quarter, compared to the consensus estimate of $447.22 million. The business's quarterly revenue was up 107.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($2.21) earnings per share. As a group, equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.82 EPS for the current year.

Wall Street Analysts Forecast Growth

ALNY has been the topic of a number of recent research reports. Morgan Stanley upped their target price on shares of Alnylam Pharmaceuticals from $250.00 to $255.00 and gave the stock an "equal weight" rating in a research report on Friday, July 12th. Barclays upped their price objective on shares of Alnylam Pharmaceuticals from $291.00 to $295.00 and gave the stock an "overweight" rating in a report on Friday, August 2nd. Canaccord Genuity Group lifted their target price on shares of Alnylam Pharmaceuticals from $357.00 to $366.00 and gave the company a "buy" rating in a report on Friday, August 2nd. The Goldman Sachs Group raised Alnylam Pharmaceuticals from a "neutral" rating to a "buy" rating and boosted their price target for the stock from $198.00 to $370.00 in a research report on Friday, August 16th. Finally, Cantor Fitzgerald lifted their price objective on Alnylam Pharmaceuticals from $150.00 to $220.00 and gave the company a "neutral" rating in a research note on Monday, July 22nd. Seven analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $278.59.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.